Results 81 to 90 of about 2,499,417 (342)

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

open access: yesMolecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva   +5 more
wiley   +1 more source

Mandatory Labelling or Import Ban?: Two-Country Trade with Biotechnology Products [PDF]

open access: yes
This paper examines trade and welfare effects of biotechnology. While biotechnology lowers production costs, it also lowers perceived quality of products. Without labelling, consumers cannot distinguish between biotechnology and conventional products. In
Jinji, Naoto
core  

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

open access: yesMolecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon   +13 more
wiley   +1 more source

AI for Life: Trends in Artificial Intelligence for Biotechnology.

open access: yesNew Biotechnology, 2023
Andreas Holzinger   +4 more
semanticscholar   +1 more source

Biotechnology and Bioengineering: Volume 117, Number 1, January 2020

open access: yesBiotechnology and Bioengineering, 2019
Lehrstuhl für Biotechnologie, RWTH Aachen University, Aachen, Germany Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China DWI Leibniz Institute for Interactive Materials, Aachen, Germany Present address: College of ...
Maximilian Boonstra   +4 more
semanticscholar   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

open access: yesMolecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková   +14 more
wiley   +1 more source

Perkembangan Bioteknologi di Indonesia

open access: yesRekayasa, 2019
Bioteknologi telah berkembang di Indonesia sejak lama namun cenderung lambat dikarenakan oleh beberapa faktor. Faktor pertama adalah minimnya dana penelitian dalam bidang bioteknologi.
Ummi Wasilah   +2 more
doaj   +1 more source

How a fungus shapes biotechnology: 100 years of Aspergillus niger research

open access: yesFungal Biology and Biotechnology, 2018
In 1917, a food chemist named James Currie made a promising discovery: any strain of the filamentous mould Aspergillus niger would produce high concentrations of citric acid when grown in sugar medium.
T. Cairns, Corrado Nai, V. Meyer
semanticscholar   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

Space and biotechnology: An industry profile [PDF]

open access: yes
The results of a study conducted by the Center for Space and Advanced Technology (CSAT) for NASA-JSC are presented. The objectives were to determine the interests and attitudes of the U.S.
Johnston, Richard S.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy